PCRX
Pacira BiosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
11
U.S. public peers
Grade Position
In line
vs peer average
PCRX vs peer average
66/100
PCRX vs. peer average (B vs. C)
Grade spread
A 2 · B 2 · C 2 · D 4 · F 1
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
NTLA is the first available peer comparator.
Intellia is another loose same-cap biotech comp with clinical-event sensitivity, but modality and commercialization differ materially from Pacira’s pain portfolio, limiting direct read-through.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
PCRX
Pacira Biosciences
NTLA
Intellia Therapeutics
Grade
B
D
Momentum
32
17
Value
70
41
Sentiment
67
65
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Defensive
Grade position vs NTLA
PCRX / NTLA
Grade Position
In line
PCRX vs. peer average (B vs. C)
66/100
Momentum
32
PCRXValue
70
PCRXSentiment
67
PCRXRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs PCRX
NTLA is the first peer returned for this comparison set.